AIFF Stock Catalyst: Firefly Neuroscience and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience, Inc. (NASDAQ: AIFF) and NeuroSigma, Inc. announced on September 25, 2026, a partnership to expand access to the Monarch eTNS System, the first FDA-cleared, non-drug treatment for pediatric ADHD.

The Monarch eTNS System is a non-invasive treatment that uses external Trigeminal Nerve Stimulation to help manage ADHD symptoms in children. The collaboration between Firefly Neuroscience and NeuroSigma is expected to enhance the distribution and accessibility of this innovative treatment option.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.